Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG.

PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12.

2.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

3.

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.

Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.

Cancer Res. 2006 Feb 1;66(3):1721-9. Erratum in: Cancer Res. 2006 Jun 1;66(11):5976.

4.

A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer.

Oh YM, Song YJ, Lee SB, Jeong Y, Kim B, Kim GW, Kim KE, Lee JM, Cho MY, Choi J, Nam DH, Song PH, Cheong KH, Kim KA.

Mol Cells. 2012 Dec;34(6):523-9. doi: 10.1007/s10059-012-0194-z. Epub 2012 Nov 22.

5.

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.

Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J.

Clin Cancer Res. 2014 Dec 1;20(23):6059-70. doi: 10.1158/1078-0432.CCR-14-0543. Epub 2014 Sep 17.

6.

Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.

Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH, Kim DU, Park HW, Han YK, Kim GW, Choi H, Song PH, Kim KA.

Oncogene. 2014 Jan 2;33(1):34-43. doi: 10.1038/onc.2012.551. Epub 2012 Dec 3.

PMID:
23208509
7.

Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, Putz H Jr, Campbell M, Karam GA, Chrunyk B, Gebhard DF, Green LL, Xu JJ, Dunn MC, Coskran TM, Lapointe JM, Cohen BD, Coleman KG, Bedian V, Vincent P, Kajiji S, Steyn SJ, Borzillo GV, Los G.

MAbs. 2012 Nov-Dec;4(6):710-23. doi: 10.4161/mabs.22160. Epub 2012 Sep 24.

8.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

9.

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.

Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E.

J Biol Chem. 2010 Nov 12;285(46):36149-57. doi: 10.1074/jbc.M110.134031. Epub 2010 Sep 10.

10.

Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK.

Neoplasia. 2009 Apr;11(4):355-64.

11.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

PMID:
26141862
12.

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.

Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):154-60. doi: 10.1016/j.bbrc.2015.06.107. Epub 2015 Jun 18.

PMID:
26093299
13.

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R.

Mol Cancer Ther. 2009 Feb;8(2):376-85. doi: 10.1158/1535-7163.MCT-08-0627. Epub 2009 Feb 3.

14.

Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.

Mai E, Zheng Z, Chen Y, Peng J, Severin C, Filvaroff E, Romero M, Mallet W, Kaur S, Gelzleichter T, Nijem I, Merchant M, Young JC.

Mol Cancer Ther. 2014 Feb;13(2):540-52. doi: 10.1158/1535-7163.MCT-13-0494. Epub 2013 Nov 20.

15.

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.

Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2009 May;8(5):1119-25. doi: 10.1158/1535-7163.MCT-08-1032. Epub 2009 May 12.

16.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L.

Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3.

17.

In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.

Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J.

FASEB J. 2002 Jan;16(1):108-10. Epub 2001 Nov 29.

18.

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.

Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Laterra J.

Clin Cancer Res. 2006 Feb 15;12(4):1292-8.

19.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

20.

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.

Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8.

Items per page

Supplemental Content

Write to the Help Desk